申请人:SHANGHAI ECUST BIOMEDICINE CO., LTD.
公开号:US20210230122A1
公开(公告)日:2021-07-29
Disclosed is a 5-fluorouracil derivative having the molecular structure shown in general formula VI, in which Ra and Rb groups are an alkoxy group or a fluorine-substituted alkoxy group having 1, 2, 3, or 4 carbon atoms, and are mono-, bis-, tri-, tetra- or penta-substituted on a phenyl group; a linking group L1 is an alkyl or alkenyl group having 1, 2, 3, or 4 carbon atoms, a linking group L2 is oxygen, or an alkyl or alkoxy group having 1, 2, 3, or 4 carbon atoms, or an amino acid, or an alkyl group having 1, 2, 3, or 4 carbon atoms containing an amino moiety, or a furyl group, and an X group is O or —NH—. Further disclosed is a method for preparing such a derivative and a use of the same in the treatment of cancer, tumor diseases, and diseases caused by abnormal neovascularization in a human or non-human mammal, and a medicament or a composition containing the 5-fluorouracil derivative.
本发明披露了一种具有分子结构的5-氟尿嘧啶衍生物,通式为VI,其中Ra和Rb基团是具有1、2、3或4个碳原子的烷氧基或氟代烷氧基,并且在苯基上是单、双、三、四或五取代的;连接基L1是具有1、2、3或4个碳原子的烷基或烯基,连接基L2是氧,或具有1、2、3或4个碳原子的烷基或烷氧基,或氨基酸,或含有氨基部分的具有1、2、3或4个碳原子的烷基,或呋喃基,X基是O或—NH—。此外,还披露了一种制备此类衍生物的方法,以及在人类或非人类哺乳动物中治疗癌症、肿瘤疾病和由异常新血管生成引起的疾病中使用该衍生物的用途,以及包含5-氟尿嘧啶衍生物的药物或组合物。